Be Bio Terminates BE-101 Hemophilia B Program

Summary Be Biopharma terminated the Phase 1/2 BeCoMe-9 study of BE-101, the first engineered B cell medicine tested clinically in hemophilia B. What Happened The trial stopped after enrolling five patients. The company stated the decision was strategic and not driven by safety concerns. Deep…